GSK241101C54000
- 0.00
- 0.000.00%
GlaxoSmithKline Newsroom
Guggenheim Downgrades GlaxoSmithKline(GSK.US) to Hold Rating
BofA Securities Maintains GlaxoSmithKline(GSK.US) With Sell Rating
Moderna's Stock-Price Target Slashed. It's About Vaccines. -- Barrons.com
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)
Moderna Stock Price Target Slashed. It's About Vaccines. -- Barrons.com
GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
Barclays Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Gritstone Oncology (GRTS) and Immutep (IMMP)
GlaxoSmithKline (GSK) Gets a Hold From Kepler Capital
Deutsche Bank Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) Receives a Hold From Goldman Sachs
GlaxoSmithKline (GSK) Gets a Hold From Barclays
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GB:GSK), Sonova Holding AG (Six Swiss: CH:SOON) and Corbus Pharmaceuticals (CRBP)
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Jefferies Sticks to Their Buy Rating for GlaxoSmithKline (GSK)
Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) Gets a Hold From Barclays
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market Share and Litigation Concerns
Berenberg Bank Maintains GlaxoSmithKline(GSK.US) With Buy Rating, Maintains Target Price $46